American Association for Cancer Research (AACR)

Ovarian cancer doesn’t announce itself. There’s no routine screening test, no reliable early warning—just symptoms vague enough to blame on something else. It is often called the “silent killer” because many cases are found only after the disease has adv...

Since the turn of the millennium, antibody-drug conjugates (ADCs) have come to occupy a substantial niche in the world of targeted cancer treatments, with 14 ADCs approved to treat several cancer types by the U.S. Food and Drug Administration (FDA) at the time of this writing.

An

A central element of the American Association for Cancer Research (AACR)’s mission is raising public awareness about the importance of cancer research. AACR does this in many ways, including through this blog, through its scientific and patient-facing publications, and through outreach to the media.

With “AACR in the News,” Cancer Research Catalyst highli...

Killing cells is easy. So easy, in fact, that our bodies do it billions of times per day, every day. And cancer cells, though notoriously hardy and crafty in their ability to survive, are still cells. So what’s the issue?

One of the central challenges of cancer treatment is not killing cells per se but killing the right cells. Chemotherapies attempt to ci...

The inaugural AACR Drug Discovery and Development (AACR D3) meeting, held July 21-24 in Boston, showcased a wide range of therapeutic innovations through its plenary sessions, keynote lectures, panel discussions, poster sessions, and more.

A unique set of Biotech S...